PureWick System for Urinary Incontinence

(PUREST-M Trial)

Enrolling by invitation at 7 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines the effectiveness of the PureWick™ Male External Catheter for men experiencing nighttime urinary incontinence. Researchers aim to assess user satisfaction and evaluate the device's safety for home use. Participants will use both the PureWick System (a device for managing urinary incontinence) and the UltraFlex Self-Adhering Male External Catheter in different sequences to compare experiences. Men who currently use diapers or pads at night for urine management may be suitable candidates for this trial. As an unphased trial, this study provides participants the chance to contribute to the understanding and improvement of urinary incontinence solutions.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the study team or your doctor.

What prior data suggests that the PureWick System and UltraFlex Self-Adhering Male External Catheter are safe for use in a home setting?

Research has shown that the PureWick System is safe and effective. One study found it to be a reliable and easy-to-use option for managing urine without invasive procedures. No major safety issues have been reported, although information on possible side effects is limited. Users should avoid using the device with materials that block airflow.

Some users of the UltraFlex Male External Catheter have reported discomfort. However, its silicone construction can help prevent skin irritation. The catheter is designed for comfort and to ensure a steady flow of urine.

Both products manage urinary incontinence without invasive methods, reducing the risk of common problems. Users should follow the guidelines and monitor for any discomfort or irritation.12345

Why are researchers excited about this trial?

Researchers are excited about the PureWick System for urinary incontinence because it offers a non-invasive alternative to traditional methods like absorbent pads or catheters. Unlike these standard options, the PureWick System uses an external catheter that wicks urine away from the body, reducing skin irritation and the risk of infections. This innovative approach provides comfort and hygiene without the need for invasive procedures, making it a promising option for those managing urinary incontinence.

What evidence suggests that this trial's treatments could be effective for urinary incontinence?

Research has shown that the PureWick System effectively manages urinary incontinence. In one study, 96.8% of participants used it successfully, indicating ease of use. Another study found that 64% of users preferred PureWick over traditional pads, demonstrating high satisfaction. The system also provides a non-invasive way to manage incontinence and helps reduce skin irritation. In this trial, participants will use both the PureWick System and the UltraFlex catheter, designed specifically for men to offer a comfortable and effective solution for male incontinence. Both PureWick and UltraFlex present promising options for managing urinary incontinence at home, and this trial will compare their effectiveness and user satisfaction.56789

Who Is on the Research Team?

AW

Adrian Wagg

Principal Investigator

University of Alberta

Are You a Good Fit for This Trial?

Adult males over 18 who use diapers or pads at night for urinary incontinence and are willing to follow study procedures. They must not have conditions that lead to very high urine output, be part of a vulnerable population, have used similar devices recently, or have certain genital issues.

Inclusion Criteria

Currently use diapers, pads, or equivalent at night for urine output management
Willing to comply with all study procedures in this protocol
I am a man over 18 and can consent to participate.
See 2 more

Exclusion Criteria

Any other condition that, in the opinion of the investigator, would preclude them from participating in the study
Is considered a vulnerable population
I usually pass more than 1500 mL of urine overnight.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment Phase 1

Participants use the first assigned urine management device overnight for 7 days

7 days
Daily assessments (virtual)

Washout

A 2-day washout period between treatment phases

2 days

Treatment Phase 2

Participants use the second assigned urine management device overnight for 7 days

7 days
Daily assessments (virtual)

Follow-up

Participants are monitored for safety and effectiveness after treatment

1-2 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • PureWick System
  • UltraFlex Self-Adhering Male External Catheter

Trial Overview

The trial is evaluating the PureWick™ Male External Catheter against an established catheter brand (UltraFlex) for managing nighttime urinary incontinence in men at home. It focuses on device performance and user satisfaction.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Treatment Sequence 2Experimental Treatment2 Interventions
Group II: Treatment Sequence 1Experimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

C. R. Bard

Lead Sponsor

Trials
109
Recruited
40,200+

Timothy M. Ring

C. R. Bard

Chief Executive Officer since 2003

Bachelor of Science in Industrial and Labor Relations from Cornell University

Dr. Cimler

C. R. Bard

Chief Medical Officer since 2017

Ph.D. in Pharmacology

Becton, Dickinson and Company

Industry Sponsor

Trials
80
Recruited
92,000+

Tom Polen

Becton, Dickinson and Company

Chief Executive Officer since 2020

Bachelor’s degree from Salisbury University, MBA from Johns Hopkins University

Meera Gopalakrishnan

Becton, Dickinson and Company

Chief Medical Officer

Ph.D. in Biomedical Engineering from the University of Memphis

Citations

Safety, Efficacy, and Patient-Reported Outcomes of the ...

The data show that 96.8% (947/978) of placements were completed by the participant in the PureWick group and 91.3% (420/460) for the Hollister FUP group.

AN OBSERVATIONAL STUDY OF THE PUREWICK™ ...

The overall opinion of PureWick was positive compared with pads, with 64% of care/nursing home users choosing to continue using PureWick beyond ...

Clinical outcomes of female external urine wicking devices as ...

Of 2,580 returned records, utilization rates decreased 14% indwelling CAUTI rates nonsignificantly decreased up to 32% CAUTIs per 1,000 pd ...

Outpatient PureWick™ female external catheter system ...

The PureWick™ female external catheter provides a non-invasive method to manage female urinary incontinence, measure urinary output, and reduce skin ...

An Evaluation of the PureWick™ Male External Catheter ...

This post-market study will assess the performance of and user satisfaction with the PureWick™ Male External Catheter in a home setting.

Safety Information - Purewick

Warnings: Do not use the PureWick™ Female External Catheter with bedpan or any material that does not allow for sufficient airflow.

Adverse Events Associated With Female External Urinary...

The PureWick device was developed with the goal of reducing the risk of UTIs that are classically associated with IUCs, as well as skin irritation and ...

The BD PureWick™ System - Official Site

Important Safety Information. Indications: The PureWick™ Flex Female External Catheter is intended for non-invasive urine output management in adult users with ...

9.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/39945631/

Adverse Events Associated With Female External Urinary ...

There is a lack of clinical data evaluating the safety of the PureWick device. Objectives: This study aimed to evaluate adverse events ...